BACKGROUND: There is no consistent evidence of specific gene(s) or molecular pathways that contribute to the pathogenesis, therapeutic intervention or diagnosis of chronic fatigue syndrome (CFS). While multiple studies support a role for genetic variation in CFS, genome-wide efforts to identify associated loci remain unexplored. We employed a novel convergent functional genomics approach that incorporates the findings from single-nucleotide polymorphism (SNP) and mRNA expression studies to identify associations between CFS and novel candidate genes for further investigation. METHODS: We evaluated 116,204 SNPs in 40 CFS and 40 nonfatigued control subjects along with mRNA expression of 20,160 genes in a subset of these subjects (35 CFS subjects and 27 controls) derived from a population-based study. RESULTS: Sixty-five SNPs were nominally associated with CFS (p<0.001), and 165 genes were differentially expressed (≥4-fold; p≤0.05) in peripheral blood mononuclear cells of CFS subjects. Two genes, glutamate receptor, ionotropic, kinase 2 (GRIK2) and neuronal PAS domain protein 2 (NPAS2), were identified by both SNP and gene expression analyses. Subjects with the G allele of rs2247215 (GRIK2) were more likely to have CFS (p=0.0005), and CFS subjects showed decreased GRIK2 expression (10-fold; p=0.015). Subjects with the T allele of rs356653 (NPAS2) were more likely to have CFS (p=0.0007), and NPAS2 expression was increased (10-fold; p=0.027) in those with CFS. CONCLUSION: Using an integrated genomic strategy, this study suggests a possible role for genes involved in glutamatergic neurotransmission and circadian rhythm in CFS and supports further study of novel candidate genes in independent populations of CFS subjects.
BACKGROUND: There is no consistent evidence of specific gene(s) or molecular pathways that contribute to the pathogenesis, therapeutic intervention or diagnosis of chronic fatigue syndrome (CFS). While multiple studies support a role for genetic variation in CFS, genome-wide efforts to identify associated loci remain unexplored. We employed a novel convergent functional genomics approach that incorporates the findings from single-nucleotide polymorphism (SNP) and mRNA expression studies to identify associations between CFS and novel candidate genes for further investigation. METHODS: We evaluated 116,204 SNPs in 40 CFS and 40 nonfatigued control subjects along with mRNA expression of 20,160 genes in a subset of these subjects (35 CFS subjects and 27 controls) derived from a population-based study. RESULTS: Sixty-five SNPs were nominally associated with CFS (p<0.001), and 165 genes were differentially expressed (≥4-fold; p≤0.05) in peripheral blood mononuclear cells of CFS subjects. Two genes, glutamate receptor, ionotropic, kinase 2 (GRIK2) and neuronal PAS domain protein 2 (NPAS2), were identified by both SNP and gene expression analyses. Subjects with the G allele of rs2247215 (GRIK2) were more likely to have CFS (p=0.0005), and CFS subjects showed decreased GRIK2 expression (10-fold; p=0.015). Subjects with the T allele of rs356653 (NPAS2) were more likely to have CFS (p=0.0007), and NPAS2 expression was increased (10-fold; p=0.027) in those with CFS. CONCLUSION: Using an integrated genomic strategy, this study suggests a possible role for genes involved in glutamatergic neurotransmission and circadian rhythm in CFS and supports further study of novel candidate genes in independent populations of CFS subjects.
Authors: William C Reeves; Dieter Wagner; Rosane Nisenbaum; James F Jones; Brian Gurbaxani; Laura Solomon; Dimitris A Papanicolaou; Elizabeth R Unger; Suzanne D Vernon; Christine Heim Journal: BMC Med Date: 2005-12-15 Impact factor: 8.775
Authors: William C Reeves; Christine Heim; Elizabeth M Maloney; Laura Solomon Youngblood; Elizabeth R Unger; Michael J Decker; James F Jones; David B Rye Journal: BMC Neurol Date: 2006-11-16 Impact factor: 2.474
Authors: Katrine Brække Norheim; Stephanie Le Hellard; Gunnel Nordmark; Erna Harboe; Lasse Gøransson; Johan G Brun; Marie Wahren-Herlenius; Roland Jonsson; Roald Omdal Journal: Rheumatol Int Date: 2013-09-03 Impact factor: 2.631
Authors: Vincent C Lombardi; Kenny L De Meirleir; Krishnamurthy Subramanian; Sam M Nourani; Ruben K Dagda; Shannon L Delaney; András Palotás Journal: J Nutr Biochem Date: 2018-04-19 Impact factor: 6.048
Authors: Santiago Herrera; Wilfred C de Vega; David Ashbrook; Suzanne D Vernon; Patrick O McGowan Journal: Epigenetics Date: 2018-12-05 Impact factor: 4.528
Authors: David Benjamin Fischer; Arsani Hany William; Adam Campbell Strauss; Elizabeth R Unger; Leonard Jason; Gailen D Marshall; Jordan D Dimitrakoff Journal: Fatigue Date: 2014-06-01